PsyBio Therapeutics Reaches Agreement to Conduct Initial Psilocybin Clinical Trial
Sep 19, 2022
PsyBio Therapeutics Latest U.S. PCT (Non-Provisional) Patent Application Accepted
Sep 7, 2022
PsyBio Therapeutics to Present at Upcoming Investor Events in September 2022
Aug 29, 2022
PsyBio Therapeutics Reports Second Quarter 2022 Financial Results
Aug 11, 2022
PsyBio Therapeutics Strengthens IP Portfolio through Filing of Data to Support Previously Submitted Provisional Biosynthetic Production Patent Application
Aug 8, 2022
PsyBio Therapeutics Announces Expansion of Patent Portfolio with Additional Global Patent Applications
Jun 27, 2022
PsyBio Therapeutics to Seek Approval of Proposed Share Consolidation at Annual and Special Meeting of Shareholders
Jun 2, 2022
PsyBio Therapeutics Initiates Commercial Biosynthetic Based Process Development for Psycho-Targeted and Psychoactive Compounds
May 30, 2022
PsyBio Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update on Intellectual Property and Clinical Development Milestones
May 16, 2022
PsyBio Therapeutics Develops Commercial Purification Process for Second Generation Psycho-Targeted Compound
May 6, 2022
PsyBio Therapeutics Initiates Blood-Brain Barrier Permeability Testing for Pipeline Compounds to Enhance Portfolio Development
Apr 29, 2022
KCSA Psychedelics Virtual Investor Conference Presentations Now Available for On-Demand Viewing
